TICKERNOMICS Sign up
Last Update: 2024-03-28 02:10:40
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) https://arrowheadpharma.com
27.84USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
ARWR
14.76%
SPY
32.74%
-55.77%
ARWR
SPY
92.93%
ARWR
51.72%
SPY
224.41%
ARWR
78.23%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3034.72
2860.57
0.71
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-10.22
16.70
10.57
-13.46
0.00
-9.99
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-3845.25
100.00
-157.52
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.7762
-130.69
-71.53
0.94
Other Earnings and Cash Flow Stats:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Net Income TTM ($MM) is -228.95
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Operating Income TTM ($MM) is -233.22
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Owners' Earnings Annual ($MM) is -227.95
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Current Price to Owners' Earnings ratio is -13.13
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) EBITDA TTM ($MM) is -221.64
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) EBITDA Margin is -157.52%
Capital Allocation:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has paid 0.00 dividends per share and bought back -1.461 million shares in the past 12 months
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has increased its debt by 36.444 million USD in the last 12 months
Capital Structure:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Interest-bearing Debt ($MM) as of last quarter is 118
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Annual Working Capital Investments ($MM) are 297
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Book Value ($MM) as of last quarter is 287
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Debt/Capital as of last quarter is 73%
Other Balance Sheet Stats:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has 58 million in cash on hand as of last quarter
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has 63 million of liabilities due within 12 months, and long term debt 0 as of last quarter
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has 107 common shares outstanding as of last quarter
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) has 0 million USD of preferred stock value
Academic Scores:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Altman Z-Score is 0.26 as of last quarter
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) largest shareholder is owning shares at 0.00 ($MM) value
Lu Hongbo(an insider) Bought 1000 shares of ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) for the amount of $27500.00 on 2024-03-20
4.96% of ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) is held by insiders, and 70.74% is held by institutions
ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) went public on 1993-06-16
Other ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) financial metrics:
FCF:-416.36
Unlevered Free Cash Flow:-782.93
EPS:-4.94
Operating Margin:-3845.25
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-331.32
Beta:0.94
Buffet's Owners Earnings:-227.95
Price to Owner's Earnings:-13.13
About ARROWHEAD PHARMACEUTICALS INC. ( ARWR ) :
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.